Showing 13,021 - 13,040 results of 63,267 for search '(( a ((((linear decrease) OR (mean decrease))) OR (larger decrease)) ) OR ( a large decrease ))', query time: 0.98s Refine Results
  1. 13021

    DataSheet_1_NOTCH1 mutation associates with impaired immune response and decreased relapse-free survival in patients with resected T1-2N0 laryngeal cancer.zip by Xiao-yang Gong (13103400)

    Published 2022
    “…Due to the small number of patients in this study, these differences need to be further validated in a larger cohort.</p>…”
  2. 13022

    Table_1_Mechanisms of Pond Expansion in a Rapidly Submerging Marsh.XLSX by Joshua Himmelstein (11497774)

    Published 2021
    “…Previous studies propose that large ponds expand through a wind wave-driven positive feedback, where pond edge erosion rates increase with pond size, whereas biochemical processes control the formation and expansion of smaller ponds. …”
  3. 13023

    Table_3_Mechanisms of Pond Expansion in a Rapidly Submerging Marsh.XLSX by Joshua Himmelstein (11497774)

    Published 2021
    “…Previous studies propose that large ponds expand through a wind wave-driven positive feedback, where pond edge erosion rates increase with pond size, whereas biochemical processes control the formation and expansion of smaller ponds. …”
  4. 13024

    Table_2_Mechanisms of Pond Expansion in a Rapidly Submerging Marsh.XLSX by Joshua Himmelstein (11497774)

    Published 2021
    “…Previous studies propose that large ponds expand through a wind wave-driven positive feedback, where pond edge erosion rates increase with pond size, whereas biochemical processes control the formation and expansion of smaller ponds. …”
  5. 13025
  6. 13026
  7. 13027
  8. 13028
  9. 13029

    Demographic data of patients with POAG and OHT. by Chareenun Chirapapaisan (8843843)

    Published 2024
    “…In total, 28 eyes were included in the study, with a mean patient age of 65.71±10.2 years. After IOP reduction, all biometric parameters, except CCT and ACD, exhibited a decrease without reaching statistical significance (all p>0.05). …”
  10. 13030

    Participant and lab results flow. by Gad Murenzi (6243719)

    Published 2025
    “…</p><p>Results</p><p>Women included in this analysis (N = 4,880) had a mean age of 40 years, > 98% were on antiretroviral therapy, and 61% had a CD4 count of ≥500 cells/µL. …”
  11. 13031
  12. 13032

    Readout properties as a function of ensemble size <i>K</i>. by Adrien Wohrer (706872)

    Published 2015
    “…<p>(A) The SVD decomposes population activity into a number of modes <i>m</i> with decreasing powers </p><p></p><p></p><p><mi>λ</mi><mi>m</mi><mn>2</mn></p><p></p><p></p>. …”
  13. 13033

    Raw data. by Wei Li (7081)

    Published 2023
    “…The purpose of this study was to assess the cost-effectiveness of sugemalimab vs. placebo for consolidation treatment of stage III NSCLC from the perspective of the Chinese healthcare system.</p><p>Methods</p><p>A 3-state Markov model with a 3-week cycle length was performed to appraise the incremental cost-utility ratio (ICUR) of sugemalimab consolidation therapy based on the GEMSTONE-301 clinical trial over a 10-year time horizon. …”
  14. 13034

    Best fit and the values of the parameters. by Wei Li (7081)

    Published 2023
    “…The purpose of this study was to assess the cost-effectiveness of sugemalimab vs. placebo for consolidation treatment of stage III NSCLC from the perspective of the Chinese healthcare system.</p><p>Methods</p><p>A 3-state Markov model with a 3-week cycle length was performed to appraise the incremental cost-utility ratio (ICUR) of sugemalimab consolidation therapy based on the GEMSTONE-301 clinical trial over a 10-year time horizon. …”
  15. 13035

    Base-case analysis results without or with PAP. by Wei Li (7081)

    Published 2023
    “…The purpose of this study was to assess the cost-effectiveness of sugemalimab vs. placebo for consolidation treatment of stage III NSCLC from the perspective of the Chinese healthcare system.</p><p>Methods</p><p>A 3-state Markov model with a 3-week cycle length was performed to appraise the incremental cost-utility ratio (ICUR) of sugemalimab consolidation therapy based on the GEMSTONE-301 clinical trial over a 10-year time horizon. …”
  16. 13036

    Results of scenario analyses for cCRT population. by Wei Li (7081)

    Published 2023
    “…The purpose of this study was to assess the cost-effectiveness of sugemalimab vs. placebo for consolidation treatment of stage III NSCLC from the perspective of the Chinese healthcare system.</p><p>Methods</p><p>A 3-state Markov model with a 3-week cycle length was performed to appraise the incremental cost-utility ratio (ICUR) of sugemalimab consolidation therapy based on the GEMSTONE-301 clinical trial over a 10-year time horizon. …”
  17. 13037
  18. 13038

    Results of scenario analyses for sCRT population. by Wei Li (7081)

    Published 2023
    “…The purpose of this study was to assess the cost-effectiveness of sugemalimab vs. placebo for consolidation treatment of stage III NSCLC from the perspective of the Chinese healthcare system.</p><p>Methods</p><p>A 3-state Markov model with a 3-week cycle length was performed to appraise the incremental cost-utility ratio (ICUR) of sugemalimab consolidation therapy based on the GEMSTONE-301 clinical trial over a 10-year time horizon. …”
  19. 13039

    Baseline characteristics of participants. by Hyungjong Park (10147327)

    Published 2025
    “…In the multivariable Cox regression analysis, eGFR > 120 mL/min ∙ 1.73 m<sup>2</sup> was associated with a decreased risk of dyslipidemia (HR: 0.35; 95% CI [0.34–0.36]). …”
  20. 13040

    A major isoform of mitochondrial <i>trans</i>-2-enoyl-CoA reductase is dispensable for wax ester production in <i>Euglena gracilis</i> under anaerobic conditions by Takuya Tomiyama (3405446)

    Published 2019
    “…<div><p>Under anaerobic conditions, <i>Euglena gracilis</i> produces a large amount of wax ester through mitochondrial fatty acid synthesis from storage polysaccharides termed paramylon, to generate ATP. …”